SCHEMBL8174005

SCHEMBL8174005

COc1ccc(-c2nc3c([nH]2)c(=O)[nH]c(=O)n3N(C)C)cc1OC

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 10/20 0.52
▸ ADORA1 P30542 3/20 0.52
▸ GUSB P08236 1/20 0.48
▸ CCNE2 O96020 1/20 0.46
▸ CCNE1 P24864 1/20 0.46
▸ CDK2 P24941 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ ADORA2B P29275 1/20 0.42
▸ ALOX5 P09917 1/20 0.42
▸ EPHX2 P34913 1/20 0.42
▸ TBK1 Q9UHD2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12256659 0.84 ADORA2A (0.53) ADORA2AADORA1GUSBCCNE2CCNE1
SCHEMBL12233411 0.79 KDM4E (0.35) ADORA2AADORA1KDM4EMAPTKMT2A
SCHEMBL8182463 0.78 KDM4E (0.54) KDM4EMEN1ALDH1A1POLBMAPT
SCHEMBL8194749 0.77 ADORA2A (0.52) ADORA2AADORA1ADORA2B
SCHEMBL25090458 0.72 ADORA2A (0.75) ADORA2AADORA1KDM4EADORA2B
SCHEMBL8184239 0.67 ADORA2B (0.54) ADORA2AADORA1KDM4EALDH1A1HPGD
SCHEMBL12257516 0.67 ADORA2B (0.66) ADORA2AADORA2B
SCHEMBL10871179 0.66 TDP2 (0.47) ADORA2AADORA1GUSBKDM4EMEN1
SCHEMBL21153881 0.66 ADORA2A (0.53) ADORA2AADORA1ADORA2B
SCHEMBL16007517 0.65 GUSB (1.00) GUSBKDM4EMEN1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044061-B2 Parkinson's disease, catalepsy, dystonia, dyskinetic syndrome, restless legs syndrome, migraine, pain, dementia, neurodegenerative disorders, alcohol withdrawal and/or ischemic conditions such as e.g. stroke or cardiac ischemia. UCB PHARMA GMBH (DE) 2011-10-25 — — US disclosed
US-20080221134-A1 8-ALKYNYLXANTHINES AND DERIVATIVES RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAET BONN (DE) 2008-09-11 — — US disclosed
WO-2008077557-A1 8-ETHINYLXANTHINE DERIVATIVES AS SELECTIVE A2A RECEPTOR ANTAGONISTS SCHWARZ PHARMA AG (DE) 2008-07-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221134-A1 8-ALKYNYLXANTHINES AND DERIVATIVES SLC6A3, PARK7, SLC18A2 ADORA2A 115/4885ADORA1 314/4885GUSB 987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback